Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

IF 3.6 4区医学 Q2 PHARMACOLOGY & PHARMACY

Clinical therapeutics Pub Date : 2025-08-29 DOI:10.1016/j.clinthera.2025.07.015

Mohamed J Saadh, Ibrahim Saeed Gataa, A S Hussam, Irwanjot Kaur, Abhishek Kumar, Pragati Godara, Rahadian Zainul, Khursheed Muzammil, Yousef Zahrani

{"title":"Effect of Epigallocatechin Gallate on Glycemic Index: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.","authors":"Mohamed J Saadh, Ibrahim Saeed Gataa, A S Hussam, Irwanjot Kaur, Abhishek Kumar, Pragati Godara, Rahadian Zainul, Khursheed Muzammil, Yousef Zahrani","doi":"10.1016/j.clinthera.2025.07.015","DOIUrl":null,"url":null,"abstract":"Purpose: Epigallocatechin gallate (EGCG), a major catechin found in green tea, has been suggested to influence glycemic control. This systematic review and meta-analysis aim to evaluate the effects of EGCG on the glycemic index (GI) and related glycemic parameters.Methods: Using predefined keywords, online databases (PubMed, Scopus, Web of Science Core Collection, and Google Scholar) were searched for relevant studies, published from inception up to May 2024. Initially 1994 studies were obtained out of which 41 RCTs were decided to be included for further analyses.Findings: The meta-analysis demonstrated that EGCG supplementation led to statistically significant, but modest, reductions in fasting blood glucose (FBG), HbA1c, and HOMA-IR. Notably, the reduction in HbA1c (WMD: -0.18%, 95% CI: -0.35, -0.02; P = 0.029) was small and may not equate to clinically meaningful benefits for all populations. Furthermore, the effect on fasting insulin was not statistically significant (WMD: -0.50; 95% CI: -1.46, 0.47; P = 0.313), indicating a lack of robust or consistent impact on this parameter across studies.Implications: Although EGCG supplementation is associated with improvements in some glycemic parameters, these effects especially for HbA1c and fasting insulin are modest and may not be clinically meaningful for most population. Therefore, current evidence does not strongly support the use of EGCG as a stand-alone intervention for glycemic control.","PeriodicalId":10699,"journal":{"name":"Clinical therapeutics","volume":" ","pages":""},"PeriodicalIF":3.6000,"publicationDate":"2025-08-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.clinthera.2025.07.015","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: Epigallocatechin gallate (EGCG), a major catechin found in green tea, has been suggested to influence glycemic control. This systematic review and meta-analysis aim to evaluate the effects of EGCG on the glycemic index (GI) and related glycemic parameters.

Methods: Using predefined keywords, online databases (PubMed, Scopus, Web of Science Core Collection, and Google Scholar) were searched for relevant studies, published from inception up to May 2024. Initially 1994 studies were obtained out of which 41 RCTs were decided to be included for further analyses.

Findings: The meta-analysis demonstrated that EGCG supplementation led to statistically significant, but modest, reductions in fasting blood glucose (FBG), HbA1c, and HOMA-IR. Notably, the reduction in HbA1c (WMD: -0.18%, 95% CI: -0.35, -0.02; P = 0.029) was small and may not equate to clinically meaningful benefits for all populations. Furthermore, the effect on fasting insulin was not statistically significant (WMD: -0.50; 95% CI: -1.46, 0.47; P = 0.313), indicating a lack of robust or consistent impact on this parameter across studies.

Implications: Although EGCG supplementation is associated with improvements in some glycemic parameters, these effects especially for HbA1c and fasting insulin are modest and may not be clinically meaningful for most population. Therefore, current evidence does not strongly support the use of EGCG as a stand-alone intervention for glycemic control.

查看原文本刊更多论文

表没食子儿茶素没食子酸酯对血糖指数的影响：随机对照试验的系统回顾和荟萃分析。

目的：表没食子儿茶素没食子酸酯（EGCG）是绿茶中发现的一种主要的儿茶素，被认为可以影响血糖控制。本系统综述和荟萃分析旨在评估EGCG对血糖指数（GI）和相关血糖参数的影响。方法：使用预定义的关键词，在PubMed、Scopus、Web of Science Core Collection和谷歌Scholar等在线数据库中检索从成立到2024年5月发表的相关研究。最初获得了1994项研究，其中41项随机对照试验被决定纳入进一步分析。研究结果：荟萃分析表明，补充EGCG导致空腹血糖（FBG）、糖化血红蛋白（HbA1c）和HOMA-IR的降低具有统计学意义，但幅度不大。值得注意的是，HbA1c的降低（WMD: -0.18%, 95% CI: -0.35, -0.02; P = 0.029）很小，可能不等于对所有人群都有临床意义的益处。此外，对空腹胰岛素的影响没有统计学意义（WMD: -0.50; 95% CI: -1.46, 0.47; P = 0.313），表明在所有研究中对该参数缺乏稳健或一致的影响。结论：虽然补充EGCG与某些血糖参数的改善有关，但这些影响特别是对HbA1c和空腹胰岛素的影响是适度的，对大多数人群可能没有临床意义。因此，目前的证据并不强烈支持使用EGCG作为单独干预血糖控制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Clinical therapeutics 医学-药学

CiteScore

6.00

自引率

3.10%

发文量

154

审稿时长

9 weeks

期刊介绍： Clinical Therapeutics provides peer-reviewed, rapid publication of recent developments in drug and other therapies as well as in diagnostics, pharmacoeconomics, health policy, treatment outcomes, and innovations in drug and biologics research. In addition Clinical Therapeutics features updates on specific topics collated by expert Topic Editors. Clinical Therapeutics is read by a large international audience of scientists and clinicians in a variety of research, academic, and clinical practice settings. Articles are indexed by all major biomedical abstracting databases.